Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;10(2):161-3.
doi: 10.1586/17474124.2016.1125290. Epub 2015 Dec 15.

Circulating microRNAs in nonalcoholic fatty liver disease

Johanna K DiStefano  1 , Glenn S Gerhard  2
Affiliations
Review

Circulating microRNAs in nonalcoholic fatty liver disease

Johanna K DiStefano et al. Expert Rev Gastroenterol Hepatol. 2016.

Abstract

Liver biopsy is currently recognized as the most accurate method for diagnosing and staging nonalcoholic fatty liver disease (NAFLD). However, this procedure is typically performed when disease has progressed to clinically significant stages, thereby limiting early diagnosis of patients who are at high risk for development of liver- and cardiovascular-related morbidity and mortality. Recently, microRNAs (miRNAs), short, noncoding RNAs that regulate gene expression, have been associated with histological features of NAFLD and are readily detected in the circulation. As such, miRNAs are emerging as potentially useful noninvasive markers with which to follow the progression of NAFLD. In this article, we present the evidence linking circulating miRNAs with NAFLD and discuss the potential value of circulating miRNA profiles in the development of improved methods for NAFLD diagnosis and clinical monitoring of disease progression.

Keywords: NAFLD; NASH; biomarker; epigenetics; liver fibrosis; miRNA.

PubMed Disclaimer

References

    1. Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease: Current status and future directions. J Dig Dis. 2015 Sep 25; - PubMed
    1. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015 Aug;35(3):221–35. - PubMed
    1. Gerhard GSBP, Wood GC, Xin C, Argyrouplous G, Petrick A, Strodel WE, Gabrielson JD, Ibele A, Still CD, Kingsley C, DiStefano JK. Identification of Novel Clinical Factors Associated with Hepatic Fat Accumulation in Extreme Obesity. Journal of Obesity. 2014;2014:1–8. - PMC - PubMed
    1. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World journal of gastroenterology : WJG. 2014 Jan 14;20(2):475–85. - PMC - PubMed
    1. Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet. 2010 Apr 24;375(9724):1419–20. - PubMed